Video

New superbug reaches the U.S.

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures


Researchers have found a person in the United States carrying bacteria resistant to antibiotics of last resort, according to an article on The Washington Post website.

Researchers worry that its colistin-resistance gene, known as mcr-1, could spread to other bacteria that can already evade other antibiotics.

Colistin is the antibiotic of last resort for particularly dangerous types of superbugs, including CRE, which health officials call a “nightmare bacteria.” 

CDC officials are working with health authorities to identify how the patient may have contracted the bacteria, including reviewing recent hospitalizations and other healthcare exposures.

Read the article.

 



June 7, 2016


Topic Area: Industry News


Recent Posts

3 Pillars of Stronger Cybersecurity in Healthcare

These strategies can help healthcare facilities stay ahead of evolving cyber threats.


Meridian Acquires Medical Office Building in Pasadena, CA

The property was acquired for approximately $13.35 million.


Expanded Maternity Unit Opens at Inspira Medical Center Mullica Hill

The expanded maternity unit supports a dedicated flow from arrival through delivery and recovery.


Resilience Planning in Remote Healthcare Facilities

Assumptions about equipment failures and response times change when a hospital is hundreds of miles from the nearest major city.


Missouri Southern State University Opens Roy Blunt Health Science Innovation Center

The project broke ground in April 2024.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.